{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:51:52Z","timestamp":1793213512697,"version":"4.5.0"},"reference-count":55,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Non-alcoholic fatty liver disease (NAFLD) is a highly frequent condition in patients with type 2 diabetes (T2D), but the identification of subjects at higher risk of developing the more severe forms remains elusive in clinical practice. The aim of this study was to evaluate the occurrence and severity of liver fibrosis and its predictive factors in T2D outpatients without a known history of chronic liver disease by using recommended non-invasive methods. Methods: Consecutive T2D outpatients underwent a set of measurements of clinical and laboratory parameters, FIB-4 score (Fibrosis-4 index), and liver stiffness with controlled attenuation-parameter (CAP) performed by transient elastography (FibroScan) after excluding previous causes of liver disease. Results: Among the 205 T2D outpatients enrolled in the study (median age: 64 years, diabetes duration: 11 years, HbA1c: 7.4%, and BMI: 29.6 kg\/m2), 54% had high ALT and\/or AST levels, 15.6% had liver stiffness value &gt; 10.1 kPa (severe fibrosis), 55.1% had CAP values &gt; 290 dB\/m (severe steatosis), and FIB-4 score was &gt;2 in 11.2% of subjects (&gt;2.67 in 15 subjects). Moreover, 49 (23.9%) T2D patients had clinically meaningful liver harm, with either a FIB-4 score &gt; 2 and\/or FibroScan &gt; 10.1 kPa. At regression analysis, BMI, HbA1c, creatinine, and triglycerides values were independent predictors of liver fibrosis. Conclusions: Liver fibrosis is a frequent finding in T2D outpatients without a known history of liver disease, especially in those with obesity, hypertriglyceridemia, worse glycemic control, and high creatinine levels.<\/jats:p>","DOI":"10.3390\/jcm12082858","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T01:32:03Z","timestamp":1681435923000},"page":"2858","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["High Prevalence of Severe Hepatic Fibrosis in Type 2 Diabetic Outpatients Screened for Non-Alcoholic Fatty Liver Disease"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0427-6963","authenticated-orcid":false,"given":"Clelia","family":"Asero","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy"},{"name":"Medicine and Hepatology Unit, University Hospital of Messina, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0778-4130","authenticated-orcid":false,"given":"Annalisa","family":"Giandalia","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy"},{"name":"Internal Medicine and Diabetology Unit, University Hospital of Messina, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7721-6799","authenticated-orcid":false,"given":"Irene","family":"Cacciola","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy"},{"name":"Medicine and Hepatology Unit, University Hospital of Messina, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Morace","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lorello","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia Rita","family":"Caspanello","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy"},{"name":"Medicine and Hepatology Unit, University Hospital of Messina, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6695-151X","authenticated-orcid":false,"given":"Angela","family":"Alibrandi","sequence":"additional","affiliation":[{"name":"Unit of Statistical and Mathematical Sciences, Department of Economics, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Squadrito","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy"},{"name":"Internal Medicine Unit, University Hospital of Messina, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina T.","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy"},{"name":"Internal Medicine and Diabetology Unit, University Hospital of Messina, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5114\/ceh.2020.102153","article-title":"Epidemiology of non-alcoholic fatty liver disease and risk of hepatocellular carcinoma progression","volume":"6","author":"Thandra","year":"2020","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease\u2014A global public health perspective","volume":"70","author":"Younossi","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Mohammed Eslam, Arun J. Sanyal, Jacob George, on behalf of an international consensus panel","volume":"158","author":"Eslam","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/liv.14274","article-title":"Liver fibrosis by FibroScan \u00ae independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes","volume":"40","author":"Lombardi","year":"2019","journal-title":"Liver Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.pcd.2016.12.001","article-title":"Clinical correlates of persistently elevated liver enzymes in type 2 diabetic outpatients","volume":"11","author":"Giandalia","year":"2017","journal-title":"Prim. Care Diabetes"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1111\/jdi.13562","article-title":"Liver fibrosis is independently associated with diabetic peripheral neuropathy in type 2 diabetes mellitus","volume":"12","author":"Huang","year":"2021","journal-title":"J. Diabetes Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/ndt\/gfab176","article-title":"Role of non-alcoholic fatty liver disease in the evolution of renal function in patients with diabetes mellitus","volume":"37","author":"Aubert","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_10","first-page":"32","article-title":"NAFLD and diabetes mellitus","volume":"14","author":"Tilg","year":"2016","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2337\/dc16-1787","article-title":"Management of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: A Call to Action","volume":"40","author":"Bril","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_12","unstructured":"Khneizer, G., Rizvi, S., and Gawrieh, S. (2020). Advances in Experimental Medicine and Biology, Springer."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.dld.2021.04.029","article-title":"Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)","volume":"54","author":"Marchesini","year":"2021","journal-title":"Dig. Liver Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: Causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s10620-016-4037-1","article-title":"Quantitative Imaging Biomarkers of NAFLD","volume":"61","author":"Kinner","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Thiagarajan, P., Bawden, S., and Aithal, G. (2021). Metabolic Imaging in Non-Alcoholic Fatty Liver Disease: Applications of Magnetic Resonance Spectroscopy. J. Clin. Med., 10.","DOI":"10.3390\/jcm10040632"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11567","DOI":"10.3748\/wjg.v21.i41.11567","article-title":"Non-invasive diagnosis of liver fibrosis and cirrhosis","volume":"21","author":"Lurie","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s40618-021-01501-y","article-title":"Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care","volume":"44","author":"Morieri","year":"2021","journal-title":"J. Endocrinol. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cld.2017.08.004","article-title":"Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease\/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography","volume":"22","author":"Tsai","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.2174\/1381612825666190117102111","article-title":"Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts","volume":"24","author":"Papatheodoridi","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/cld.1045","article-title":"Nonalcoholic Fatty Liver Disease and Recent Guideline Updates","volume":"17","author":"Ando","year":"2021","journal-title":"Clin. Liver Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.toxrep.2021.02.010","article-title":"Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy","volume":"8","author":"Subramaniyan","year":"2021","journal-title":"Toxicol. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.dld.2007.05.006","article-title":"Drinking habits and risk of altered liver enzymes in the general population of a rural area in Southern Italy","volume":"39","author":"Loguercio","year":"2007","journal-title":"Dig. Liver Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/hep.31150","article-title":"Epidemiological Features of NAFLD From 1999 to 2018 in China","volume":"71","author":"Zhou","year":"2020","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"154299","DOI":"10.1016\/j.metabol.2020.154299","article-title":"Metabolic liver disease in diabetes\u2014From mechanisms to clinical trials","volume":"111","author":"Dewidar","year":"2020","journal-title":"Metab. Clin. Exp."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2022). Standards of Medical Care in Diabetes\u20142022 Abridged for Primary Care Providers. Clin. Diabetes, 40, 10\u201338.","DOI":"10.2337\/cd22-as01"},{"key":"ref_28","unstructured":"(2022, May 15). Standard Italiani per la Cura del Diabete Mellito 2018. AMD-SID. Available online: https:\/\/www.siditalia.it\/clinica\/standard-dicura-amd-sid."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Use of the fib4 index for non-invasive evaluation of fibrosis in nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease","volume":"59","author":"McPherson","year":"2010","journal-title":"Gut"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.gtc.2019.02.002","article-title":"Liver Fibrosis Determination","volume":"48","author":"Lai","year":"2019","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_33","first-page":"1006","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: An individual patient data meta-analysis","volume":"71","author":"Lee","year":"2021","journal-title":"Gut"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ultrasmedbio.2010.07.005","article-title":"Controlled Attenuation Parameter (CAP): A Novel VCTE\u2122 Guided Ultrasonic Attenuation Measurement for the Evaluation of Hepatic Steatosis: Preliminary Study and Validation in a Cohort of Patients with Chronic Liver Disease from Various Causes","volume":"36","author":"Sasso","year":"2010","journal-title":"Ultrasound Med. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1111\/liv.14943","article-title":"Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)","volume":"41","author":"Burra","year":"2021","journal-title":"Liver Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1900\/RDS.2022.18.140","article-title":"Prevalence and Specific Manifestations of Non-alcoholic Fatty Liver Disease (NAFLD) and Diabetes Mellitus Type 2 Association in a Moroccan Population: A Cross-sectional Study","volume":"18","author":"Assarrar","year":"2022","journal-title":"Rev. Diabet. Stud."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40618-017-0799-3","article-title":"NAFLD\/NASH in patients with type 2 diabetes and related treatment options","volume":"41","author":"Radaelli","year":"2017","journal-title":"J. Endocrinol. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.amjmed.2020.01.007","article-title":"Nonalcoholic fatty liver disease: What does the primary care physician need to know?","volume":"133","author":"Budd","year":"2020","journal-title":"Am. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.20734","article-title":"Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study","volume":"42","author":"Bedogni","year":"2005","journal-title":"Hepatology"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Fuloria, S., Subramaniyan, V., Karupiah, S., Kumari, U., Sathasivam, K., Meenakshi, D., Wu, Y., Guad, R., Udupa, K., and Fuloria, N. (2020). A Comprehensive Review on Source, Types, Effects, Nanotechnology, Detection, and Therapeutic Management of Reactive Carbonyl Species Associated with Various Chronic Diseases. Antioxidants, 9.","DOI":"10.3390\/antiox9111075"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1210\/er.2019-00034","article-title":"The Liver as an Endocrine Organ\u2014Linking NAFLD and Insulin Resistance","volume":"40","author":"Watt","year":"2019","journal-title":"Endocr. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"8377","DOI":"10.3748\/wjg.v20.i26.8377","article-title":"Non-alcoholic fatty liver disease and diabetes: From physiopathological interplay to diagnosis and treatment","volume":"20","author":"Leite","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1210\/er.2012-1009","article-title":"Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo","volume":"34","author":"Williams","year":"2012","journal-title":"Endocr. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.diabres.2017.10.023","article-title":"Trend over time in hepatic fibrosis score in a cohort of type 2 diabetes patients","volume":"135","author":"Giorda","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e2878","DOI":"10.1002\/dmrr.2878","article-title":"Occurrence over time and regression of nonalcoholic fatty liver disease in type 2 diabetes","volume":"33","author":"Giorda","year":"2016","journal-title":"Diabetes\/Metabolism Res. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Meroni, M., Longo, M., Rustichelli, A., and Dongiovanni, P. (2020). Nutrition and Genetics in NAFLD: The Perfect Binomium. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082986"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/liv.12226","article-title":"Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)","volume":"33","author":"Verma","year":"2013","journal-title":"Liver Int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1111\/liv.14905","article-title":"Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus\/diabetic individuals with chronic hepatitis or with cirrhosis","volume":"41","author":"Cacciola","year":"2021","journal-title":"Liver Int."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Tana, C., Ballestri, S., Ricci, F., Di Vincenzo, A., Ticinesi, A., Gallina, S., Giamberardino, M.A., Cipollone, F., Sutton, R., and Vettor, R. (2019). Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16173104"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.3748\/wjg.v26.i23.3249","article-title":"Medications in type-2 diabetics and their association with liver fibrosis","volume":"26","author":"Siddiqui","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","article-title":"Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications","volume":"45","author":"Scheen","year":"2019","journal-title":"Diabetes Metab."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Licata, A., Russo, G.T., Giandalia, A., Cammilleri, M., Asero, C., and Cacciola, I. (2023). Impact of Sex and Gender on Clinical Management of Patients with Advanced Chronic Liver Disease and Type 2 Diabetes. J. Pers. Med., 13.","DOI":"10.3390\/jpm13030558"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., and Targher, G. (2021). Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. Metabolites, 11.","DOI":"10.3390\/metabo11020073"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/8\/2858\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:15:25Z","timestamp":1760123725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/8\/2858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":55,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["jcm12082858"],"URL":"https:\/\/doi.org\/10.3390\/jcm12082858","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]}}}